Skip to main content

Characterization of Patients with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and Thrombotic Microangiopathy (TMA) Associated with HSCT (HSCT-TMA) in TriNetX: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Health Outcome(s)
hematopoietic stem cell transplantation
thrombotic microangiopathy
Description

In this analysis, we aimed to assess demographic and clinical characteristics of patients with allogeneic hematopoietic stem cell transplantation (HSCT) as well as of patients with confirmed thrombotic microangiopathy (TMA) associated with allogeneic hematopoietic stem cell transplantation (HSCT-TMA) using the TriNetX Live™ platform.

  • Report 1: We ran this report on September 26, 2024, using data from 60 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network with Minimal Shift from July 1, 2009 to August 31, 2020.
  • Report 2: We ran this report on September 30, 2024, using data from 60 HCOs, provided through the TriNetX Live™ platform in their USA Network with Minimal Shift from September 1, 2020 to August 31, 2024.
Deliverables (2)
Sentinel Modular Program Report: Characterization of Patients with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and Thrombotic Microangiopathy (TMA) Associated with HSCT (HSCT-TMA) in TriNetX: A Descriptive Analysis, Report 1 Sentinel Modular Program Report: Characterization of Patients with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and Thrombotic Microangiopathy (TMA) Associated with HSCT (HSCT-TMA) in TriNetX: A Descriptive Analysis, Report 2
Additional Details
FDA Center
CDER
Time Period
July 1, 2009 - August 31, 2020; September 1, 2020 - August 31, 2024
Analysis Type
TriNetX Analysis
Population / Cohort
All individuals
Data Sources
TriNetX Live™ USA Network